Stockreport

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

eFFECTOR Therapeutics, Inc.  (EFTR) 
PDF Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct finan [Read more]